News Case study backs YolTech's AATD gene therapy A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.
News EVERSANA builds its AI Agency with Estima acquisition EVERSANA has acquired UK AI-powered health economics and outcomes research (HEOR) firm Estima to help its customers "modernise commercialisation."
News uniQure set for May FDA verdict on Huntington's gene therapy The FDA has started its review of uniQure's gene therapy for neurodegenerative disorder Huntington's, but will require an advisory committee meeting.
News Merck charts course out of CDMO business with Lonza sale Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.
News Cure HHT wins inaugural Prix Galien Patient First Award A patient-led initiative for hereditary haemorrhagic telangiectasia (HHT) has won the inaugural Prix Galien Patient First Award.
News Ultragenyx gets first Euro nod for rare disease drug Dojolvi Several years after its US approval, Ultragenyx's therapy for long-chain fatty acid oxidation disorders, Dojolvi, has been greenlit in the UK.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.